Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds

Area of Science:

• Immunology
• Oncology
• Cellular Therapy

Background:

• Engineered T lymphocytes, specifically Chimeric Antigen Receptor (CAR)-T cells, demonstrate clinical success in targeting CD19-positive hematologic malignancies.
• Previous reports on a pilot trial for chronic lymphocytic leukemia (CLL) showed promising clinical activity and T cell persistence.

Purpose of the Study:

• To present updated clinical data and correlative analyses from a completed pilot clinical trial of CAR-T cell therapy in CLL patients.
• To evaluate the efficacy and identify factors influencing treatment response in a larger cohort of CLL patients.

Main Methods:

• Analysis of clinical data from 14 CLL patients treated with CAR-T cells.
• Correlative analyses to assess T cell expansion, contraction, persistence, and cytokine release syndrome.
• Evaluation of molecular remissions and treatment response in partial and non-responding patients.

Main Results:

• Robust clinical activity was observed in a subset of patients, with molecular remissions documented.
• Continued T cell expansion, contraction, and long-term functional persistence were noted.
• A subset of partial and non-responding patients was identified in the expanded cohort.

Conclusions:

• Cellular immunotherapy with engineered T cells is a viable treatment option for CLL.
• Sustained in-vivo activation and persistence of engineered T cells are likely required for complete responses.
• Further mechanistic understanding of immune- and tumor-specific processes is needed to optimize CAR-T cell therapy.